Shamburg News · 8-K filed Nov 12, 2026, 7:38 AM EST

Taysha Gene Therapies Reports Third Quarter 2026 Financial Results and Corporate Update

TSHA · Taysha Gene Therapies, Inc.

  • Earnings
  • Materiality: high

Taysha Gene Therapies, Inc. reported a net loss of $39.1 million, or $0.10 per share, for the quarter ended September 30, 2026, compared with a net loss of $32.7 million, or $0.09 per share, a year earlier. Research and development expenses were $28.8 million and general and administrative expenses were $13.1 million for the quarter. As of September 30, 2026, the company had $422.8 million in cash and cash equivalents, which it expects will support operations into the second half of 2028.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Items 2.02, 9.01, accession 0001193125-26-456974.

Written from the filing by Shamburg Markets. Figures are as reported by the company.